| L-PZQ ODT in Schistosoma Infected Children (NCT03845140) | Merck KGaA, Darmstadt, Germany | 2019-09-02 |
| Efficacy and Safety of Crinone Versus Combination Medication (ACCESS) (NCT03858049) | Merck KGaA, Darmstadt, Germany | 2019-05-31 |
| Effects of Cladribine Tablets on the PK of Microgynon® (NCT03745144) | Merck KGaA, Darmstadt, Germany | 2019-01-17 |
| Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC (NCT03717155) | Merck KGaA, Darmstadt, Germany | 2018-10-30 |
| Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt) (NCT03566810) | Merck KGaA, Darmstadt, Germany | 2018-10-11 |
| Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants (NCT03676322) | Merck KGaA, Darmstadt, Germany | 2018-09-20 |
| Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib (NCT03629223) | Merck KGaA, Darmstadt, Germany | 2018-08-23 |
| Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA) (NCT03583346) | Merck KGaA, Darmstadt, Germany | 2018-08-23 |
| Effect of Tepotinib on PK of CYP3A Substrate Midazolam (NCT03628339) | Merck KGaA, Darmstadt, Germany | 2018-08-20 |
| Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study (NCT03583385) | Merck KGaA, Darmstadt, Germany | 2018-08-16 |
| Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) (NCT03369665) | Merck KGaA, Darmstadt, Germany | 2018-06-20 |
| Praziquantel Bioequivalence Study (NCT03437447) | Merck KGaA, Darmstadt, Germany | 2018-06-18 |
| Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) (NCT03364036) | Merck KGaA, Darmstadt, Germany | 2018-05-28 |
| Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate (NCT03492437) | Merck KGaA, Darmstadt, Germany | 2018-05-17 |
| Effect of a Proton Pump Inhibitor on the PK of Tepotinib (NCT03531762) | Merck KGaA, Darmstadt, Germany | 2018-05-14 |
| Phase I/Ib Multiple Ascending Dose Study in China (NCT03523390) | Merck KGaA, Darmstadt, Germany | 2018-04-24 |
| TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment (NCT03164551) | Merck KGaA, Darmstadt, Germany | 2018-04-16 |
| A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) (NCT03387046) | Merck KGaA, Darmstadt, Germany | 2018-03-26 |
| Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) (NCT03436394) | Merck KGaA, Darmstadt, Germany | 2018-03-21 |
| A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants (NCT03467971) | Merck KGaA, Darmstadt, Germany | 2018-03-06 |
| Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants (NCT03467945) | Merck KGaA, Darmstadt, Germany | 2018-02-16 |
| Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle (NCT03387059) | Merck KGaA, Darmstadt, Germany | 2018-01-12 |
| ATRi Transition Rollover Study (NCT03309150) | Merck KGaA, Darmstadt, Germany | 2018-01-10 |
| Glucophage Immediate Release (GIR) China Bioequivalence Study (NCT03393208) | Merck KGaA, Darmstadt, Germany | 2018-01-10 |
| M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsule (NCT03297983) | Merck KGaA, Darmstadt, Germany | 2017-10-09 |
| First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants (NCT03261401) | Merck KGaA, Darmstadt, Germany | 2017-09-15 |
| Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease (NCT03584321) | Merck KGaA, Darmstadt, Germany | 2017-09-13 |
| First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers (NCT03224702) | Merck KGaA, Darmstadt, Germany | 2017-09-04 |